FLK 2

Drug Profile

FLK 2

Alternative Names: T-SCR

Latest Information Update: 02 Apr 1997

Price : $50

At a glance

  • Originator ImClone Systems
  • Developer Amgen; ImClone Systems
  • Class Antineoplastics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chemotherapy-induced damage

Most Recent Events

  • 02 Apr 1997 New profile
  • 02 Feb 1995 Discontinued-Preclinical for Chemotherapy induced damage/Chemoprotection in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top